Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247736 | 0.79 | CA2 (0.43) | OPRK1CA2NLRP3HRH4MIF | |
| SCHEMBL27247096 | 0.77 | LOXL2 (0.58) | OPRK1CA2TYRCDK5CDK5R1 | |
| SCHEMBL12979838 | 0.77 | CA2 (0.46) | OPRK1CA2TYRCDK5CDK5R1 | |
| SCHEMBL27785505 | 0.77 | CA2 (0.46) | OPRK1CA2TYRCDK5CDK5R1 | |
| SCHEMBL27247248 | 0.75 | MTNR1A (0.51) | OPRK1CA2NLRP3HRH4ALOX15 | |
| SCHEMBL15598348 | 0.73 | MTNR1A (0.47) | OPRK1CA2TYRCDK5CDK5R1 | |
| SCHEMBL16884321 | 0.73 | METTL3 (0.48) | OPRK1 | |
| SCHEMBL30920730 | 0.71 | NQO2 (0.48) | OPRK1CA2HRH4MIF | |
| SCHEMBL27247390 | 0.71 | METTL3 (0.39) | OPRK1CA2HRH4MIF | |
| SCHEMBL7622759 | 0.70 | TAAR1 (0.49) | CA2TYRCDK5CDK5R1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |